Recurrent NNRTI-Induced Hepatotoxicity in an HIV-HCV-Coinfected Patient

McDonald C Kuritzkes D . Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med 1997;157: 951–9.

Flexner C . HIV-protease inhibitors. N Engl J Med 1998;338: 1281–92.

Montaner J Reiss P Cooper D Vella S Harris M Conway B A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS Trial: Italy, the Netherlands, Canada, and Australia Study. JAMA 1998;279: 930–7.

Leitze Z Nadeem A Choudhary A Saul Z Roberts I Manthous C . Nevirapine-induced hepatitis treated with corticosteroids. AIDS 1998;12: 1115–7.

Haas D Seekins D Cooper R Gallant J Tashima K Hicks C Phase II, double-blind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of efavirenz (EFV, SUSTIVA(tm), DMP 266) in combination with open-label zidovudine (ZDV) with lamivudine (3TC) at 36 weeks [DMP 266–005]. In: Proceedings of the 12th World AIDSConference, Geneva, Switzerland, June 28–July 3, 1998.

Riddler S Kahn J Hicks C Havlir D Stein D Horton J Durable clinical anti-HIV-1 activity (72 weeks) and tolerability for efavirenz (DMP 266) in combination with indinavir (IDV) [DMP 266–003, Cohort IV]. In: Proceedings of the 12th World AIDS Conference, Geneva, Switzerland, June 28–July 3, 1998.

Patel S Benfield P . Nevirapine. Clin Immunother 1996;6: 307–17.

D'Aquila R Hughes M Johnson V Fischl M Sommadossi J Liou S Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo controlled trial. Ann Intern Med 1996;12: 912–30.

Longo G Valenti C Gandini G Ferrara L Bertesi M . Azithromycin-induced intrahepatic cholestasis. Am J Med 1997;102: 217–8.

Naranjo C Busto U Sellers E Sandor P Ruiz I Roberts E A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45.

Regazzi MB Iacona I Alessiani M Spada M Vaccarisi S Villani P Interaction between FK 506 and diltiazem in an animal model. Transplant Proced 1996;28:1017–8.

Katari SR Magnone M Shapiro R Jordan M Scantlebury V Vivas C Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. Clin Transplant 1997;11:237–42.

Jensen C Jordan M Shapiro R Scantlebury V Hakala T Fung J Interaction between tacrolimus and erythromycin (letter). Lancet 1994;344:825.

Campana C Regazzi MB Buggia I Molinaro M . Clinically significant drug interactions with cyclosporin. An update. Clin Pharmacokinet 1996;30: 141–79.

Kwan JTC Foxall PJD Davidson DGC Bending MR Eisinger AJ . An interaction of cyclosporin and itraconazole (letter). Lancet 1987;2: 282.

Naranjo C Busto U Sellers E Sandor P Ruiz I Roberts E A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45.